Suchergebnisse - "Temesgen, Z"

PubPharm (119)

1

Investigational antiviral drugs for the treatment of COVID-19

enthalten in: Drugs of the future | 2021

von Vegivinti, C. | Assi, M. | Talwani, R. | +3

2

Investigational immunomodulatory therapies for COVID-19

enthalten in: Drugs of the future | 2021

von Assi, M. | Koshy, K. | El Atrouni, W. | +4

3

Emergence of dual antiretroviral therapy as a viable regimen option for the treatment of patients with HIV infection

enthalten in: Drugs of today (Barcelona, Spain : 1998) | 2020

von Fida, M. | Mahmood, M. | Temesgen, Z.

4

Doravirine : a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection

enthalten in: Drugs of today (Barcelona, Spain : 1998) | 2020

von Talwani, R. | Temesgen, Z.

5

Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection

enthalten in: Drugs of today | 2020

von Talwani, R. | Temesgen, Z.

6

Inarigivir soproxil. Retinoic acid-inducible gene I protein (RIG-I) activator, Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) activator, Treatment of chronic hepatitis B

enthalten in: Drugs of the future | 2020

von Nehra, V. | Temesgen, Z.

7

Emergence of dual antiretroviral therapy as a viable regimen option for the treatment of patients with HIV infection

enthalten in: Drugs of today | 2020

von Fida, M. | Mahmood, M. | Temesgen, Z.

8

Rovafovir etalafenamide. Nucleotide reverse transcriptase inhibitor, Treatment of HIV-1 infection

enthalten in: Drugs of the future | 2020

von Berg, M. | Temesgen, Z.

9

Bictegravir, a novel integrase inhibitor for the treatment of HIV infection

enthalten in: Drugs of today (Barcelona, Spain : 1998) | 2019

von Zeuli, J. | Rizza, S. | Bhatia, R. | +1

10

Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy

enthalten in: Drugs of today (Barcelona, Spain : 1998) | 2019

von Fida, M. | Rizza, S. | Temesgen, Z.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]